0A3S Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.58 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$3.53 |
| Beta | 2.09 |
| 11 Month Change | -13.53% |
| 3 Month Change | -29.16% |
| 1 Year Change | 53.79% |
| 33 Year Change | -96.06% |
| 5 Year Change | n/a |
| Change since IPO | -73.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A3S | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 21.5% | 0.3% | 2.2% |
| 1Y | 53.8% | -18.3% | 8.0% |
Return vs Industry: 0A3S exceeded the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0A3S exceeded the UK Market which returned 8% over the past year.
Price Volatility
| 0A3S volatility | |
|---|---|
| 0A3S Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A3S's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A3S's weekly volatility has decreased from 20% to 12% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| 0A3S fundamental statistics | |
|---|---|
| Market cap | US$1.36b |
| Earnings (TTM) | -US$284.86m |
| Revenue (TTM) | US$885.19m |
1.5x
P/S Ratio-4.8x
P/E RatioIs 0A3S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A3S income statement (TTM) | |
|---|---|
| Revenue | US$885.19m |
| Cost of Revenue | US$769.73m |
| Gross Profit | US$115.46m |
| Other Expenses | US$400.32m |
| Earnings | -US$284.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 13.04% |
| Net Profit Margin | -32.18% |
| Debt/Equity Ratio | -32.2% |
How did 0A3S perform over the long term?
See historical performance and comparison